RxDoctor Payments Data

Caitlin Szczupak, MD

Family Practice · Altoona, PANPI 1396300026

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Exact Sciences at 49.2% of the total. Among family practice clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$384in general payments, 2019–2025

Across 9 payments — averaging $42.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$189
  • Novo Nordisk$121
  • Sumitomo Pharma America, Inc.$26
  • GSK$17
  • Amgen$16
  • AstraZeneca$15

What the payments were for

  • Food & beverage$384100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$384 in reported general payments places this provider in the 95th percentile of 870 family practice providers in Pennsylvania.

See all family practice providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$145,704
Medicare patients
456
Services billed
1,808

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban83$106,751
OzempicSemaglutide94$102,473
Trelegy ElliptaFluticasone/Umeclidin/Vilanter151$99,696
EliquisApixaban60$52,255
MounjaroTirzepatide28$29,317
Breo ElliptaFluticasone/Vilanterol53$24,887
ProliaDenosumab13$20,763
TrulicityDulaglutide13$20,277
JardianceEmpagliflozin16$20,034
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$19,501
JanuviaSitagliptin Phosphate12$18,923
Spiriva RespimatTiotropium Bromide18$16,163
Fluticasone-SalmeterolFluticasone Propion/Salmeterol95$15,610
Lantus SolostarInsulin Glargine,hum.Rec.Anlog80$13,292
Repatha SyringeEvolocumab12$10,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$17$124,583204 claims
Novo NordiskOzempic$121$102,47394 claims
AmgenProlia$16$20,76313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 870 family practice providers in Pennsylvania.

Other family practice in Altoona

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →